Financial Performance - Net income attributable to common stockholders for Q1 2025 was 21.2 million in Q1 2024[9] - Total operating expenses for Q1 2025 were 9.20 million in Q1 2024[18] - The change in fair value of the warrant liability contributed to other income of 11.8 million in Q1 2024[8] Research and Development - Research and Development (R&D) expenses decreased to 6.8 million in Q1 2024, primarily due to reduced drug development costs[4] General and Administrative Expenses - General and Administrative (G&A) expenses increased to 2.4 million in Q1 2024, mainly due to higher consulting and professional services for commercial launch preparation[5] Cash and Assets - Cash and cash equivalents as of March 31, 2025, totaled 26.1 million as of December 31, 2024[10] - Prepaid expenses and other current assets increased from 7.6 million as of March 31, 2025, reflecting ongoing commercial supply manufacturing efforts[8] Regulatory and Market Preparation - The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2025, for the New Drug Application (NDA) of oxylanthanum carbonate (OLC)[7] - The company is preparing for the anticipated commercial launch of OLC in late 2025, supported by ongoing commercial planning and engagement with prescribers[6] Market Insights - New patient survey data indicated that 200 dialysis patients identified excessive pill numbers and sizes as primary barriers to adherence, highlighting the market potential for OLC[7]
Unicycive(UNCY) - 2025 Q1 - Quarterly Results